{"id":37199,"date":"2025-10-28T22:04:09","date_gmt":"2025-10-28T15:04:09","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=37199"},"modified":"2025-10-28T22:04:09","modified_gmt":"2025-10-28T15:04:09","slug":"myrio-therapeutics-announces-collaboration-with-leading-research-institutions-to-advance-solid-tumor-t-cell-immunotherapeutics","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=37199","title":{"rendered":"Myrio Therapeutics Announces Collaboration with Leading Research Institutions to Advance Solid Tumor T cell Immunotherapeutics"},"content":{"rendered":"<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2710302\/Myrio_Therapeutics_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li>Myrio Therapeutics, the <span class=\"xn-org\">University of Pennsylvania<\/span> Perelman School of Medicine, and NYU Langone Health have entered a research collaboration to accelerate the development of next-generation T cell immunotherapies<\/li>\n<li>Partnership with T cell experts Daniel J\u00a0Powell Jr., PhD, and <span class=\"xn-person\">Mark Yarmarkovich<\/span>, PhD<\/li>\n<\/ul>\n<p><span class=\"xn-location\">PHILADELPHIA<\/span>, NEW YORK\u00a0and <span class=\"xn-location\">MELBOURNE, Australia<\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Oct. 28, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Myrio Therapeutics today announced a collaborative research partnership with the <span class=\"xn-org\">University of Pennsylvania&#8217;s<\/span> Perelman School of Medicine and NYU Langone Health to accelerate the development of next generation solid tumor T cell immunotherapeutics.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<\/div>\n<p>This tri-party agreement brings together complementary expertise in peptide HLA (pHLA) binder discovery, bispecific T-cell engager development and cell immunotherapies to overcome barriers to effective and durable immunotherapies through three core pillars:<\/p>\n<ul type=\"disc\">\n<li><b>Targeting Oncogenic Drivers:<\/b>\u00a0Leveraging highly specific anti pHLA antibodies to directly attack the molecular drivers of cancer.<\/li>\n<li><b>Amplifying Innate Immune Functions:<\/b>\u00a0Coordinating approaches to harness and enhance the body&#8217;s natural immune defenses.<\/li>\n<li><b>Utilizing Novel CAR Architectures:<\/b>\u00a0Co-developing next-generation Chimeric Antigen Receptors (CARs) with heightened sensitivity to a broader range of targets, including those with low abundance.<\/li>\n<\/ul>\n<p>By combining their strengths, the three parties will generate deeper insights into these mechanisms and explore the therapeutic potential of these technologies.\u00a0The next step will be to formally establish a company and initiate seed funding to move these advances toward clinical development.\u00a0<\/p>\n<p>Myrio Tx CEO, Dr <span class=\"xn-person\">Graeme Wald<\/span> welcomed the collaboration as one where the sum of the parts is greater than the individuals. &#8220;This is a magnificent case of putting the best technologies and people together to develop products for solid tumor treatments. The next step will be to formally establish a company and initiate seed funding to move these advances toward clinical development.&#8221;<\/p>\n<p>&#8220;A major challenge in the development of cancer treatment is creating tolerable approaches that also deliver effective and long-lasting response in patients,&#8221; said Daniel J Powell Jr. Ph.D., a professor of Pathology and Laboratory Medicine in the Perelman School of Medicine at the <span class=\"xn-org\">University of Pennsylvania<\/span>. &#8220;By uniting the diverse expertise of these three groups, we are in an excellent position to create safe, effective, durable therapy for difficult-to-treat cancers.&#8221;<\/p>\n<p>&#8220;We are thrilled to move forward quickly with this collaboration, bringing together uniquely complementary technologies to tackle the challenges of solid tumors, said <span class=\"xn-person\">Mark Yarmarkovich<\/span>, Assistant Professor, NYU Langone Health. By combining our platforms, we have the opportunity to create truly differentiated therapies that can change the treatment landscape and, most importantly, make a meaningful difference for patients.&#8221;<\/p>\n<p><b>About\u00a0Myrio Therapeutics<\/b><\/p>\n<p>Myrio Therapeutics is a biotechnology company developing next-generation precision immunotherapies targeting oncogenic mutations using its proprietary pHLA binder technology. The company&#8217;s programs focus on delivering transformative therapies for solid tumors, leveraging its extensive antibody library and robust preclinical pipeline.\u00a0 For more on the company, please see: <a href=\"https:\/\/protect.checkpoint.com\/v2\/r01\/___https:\/myriotx.com___.YzJ1OndlY29tbXVuaWNhdGlvbnM6YzpvOmZmNzIyOTVhMzIwMjBjZWE2YmY2ZTZkNTY3ODM1NDNjOjc6ZDc2OTo4ZmRjNDk3NTkzZTJmNWNlZmQ3ZGI5ZjRhNDM1Y2M5NzEwYzEwZGM0ODc1NGI0NzAxMmE4M2ZhNWJmOWYzNTdjOnA6VDpG\" target=\"_blank\" rel=\"nofollow\">https:\/\/myriotx.com<\/a>\u00a0<\/p>\n<p>\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2710302\/Myrio_Therapeutics_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li>Myrio Therapeutics, the <span class=\"xn-org\">University of Pennsylvania<\/span> Perelman School of Medicine, and NYU Langone Health have entered a research collaboration to accelerate the development of next-generation T cell immunotherapies<\/li>\n<li>Partnership with T cell experts Daniel J\u00a0Powell Jr., PhD, and <span class=\"xn-person\">Mark Yarmarkovich<\/span>, PhD<\/li>\n<\/ul>\n<p><span class=\"xn-location\">PHILADELPHIA<\/span>, NEW YORK\u00a0and <span class=\"xn-location\">MELBOURNE, Australia<\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Oct. 28, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Myrio Therapeutics today announced a collaborative research partnership with the <span class=\"xn-org\">University of Pennsylvania&#8217;s<\/span> Perelman School of Medicine and NYU Langone Health to accelerate the development of next generation solid tumor T cell immunotherapeutics.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<\/div>\n<p>This tri-party agreement brings together complementary expertise in peptide HLA (pHLA) binder discovery, bispecific T-cell engager development and cell immunotherapies to overcome barriers to effective and durable immunotherapies through three core pillars:<\/p>\n<ul type=\"disc\">\n<li><b>Targeting Oncogenic Drivers:<\/b>\u00a0Leveraging highly specific anti pHLA antibodies to directly attack the molecular drivers of cancer.<\/li>\n<li><b>Amplifying Innate Immune Functions:<\/b>\u00a0Coordinating approaches to harness and enhance the body&#8217;s natural immune defenses.<\/li>\n<li><b>Utilizing Novel CAR Architectures:<\/b>\u00a0Co-developing next-generation Chimeric Antigen Receptors (CARs) with heightened sensitivity to a broader range of targets, including those with low abundance.<\/li>\n<\/ul>\n<p>By combining their strengths, the three parties will generate deeper insights into these mechanisms and explore the therapeutic potential of these technologies.\u00a0The next step will be to formally establish a company and initiate seed funding to move these advances toward clinical development.\u00a0<\/p>\n<p>Myrio Tx CEO, Dr <span class=\"xn-person\">Graeme Wald<\/span> welcomed the collaboration as one where the sum of the parts is greater than the individuals. &#8220;This is a magnificent case of putting the best technologies and people together to develop products for solid tumor treatments. The next step will be to formally establish a company and initiate seed funding to move these advances toward clinical development.&#8221;<\/p>\n<p>&#8220;A major challenge in the development of cancer treatment is creating tolerable approaches that also deliver effective and long-lasting response in patients,&#8221; said Daniel J Powell Jr. Ph.D., a professor of Pathology and Laboratory Medicine in the Perelman School of Medicine at the <span class=\"xn-org\">University of Pennsylvania<\/span>. &#8220;By uniting the diverse expertise of these three groups, we are in an excellent position to create safe, effective, durable therapy for difficult-to-treat cancers.&#8221;<\/p>\n<p>&#8220;We are thrilled to move forward quickly with this collaboration, bringing together uniquely complementary technologies to tackle the challenges of solid tumors, said <span class=\"xn-person\">Mark Yarmarkovich<\/span>, Assistant Professor, NYU Langone Health. By combining our platforms, we have the opportunity to create truly differentiated therapies that can change the treatment landscape and, most importantly, make a meaningful difference for patients.&#8221;<\/p>\n<p><b>About\u00a0Myrio Therapeutics<\/b><\/p>\n<p>Myrio Therapeutics is a biotechnology company developing next-generation precision immunotherapies targeting oncogenic mutations using its proprietary pHLA binder technology. The company&#8217;s programs focus on delivering transformative therapies for solid tumors, leveraging its extensive antibody library and robust preclinical pipeline.\u00a0 For more on the company, please see: <a href=\"https:\/\/protect.checkpoint.com\/v2\/r01\/___https:\/myriotx.com___.YzJ1OndlY29tbXVuaWNhdGlvbnM6YzpvOmZmNzIyOTVhMzIwMjBjZWE2YmY2ZTZkNTY3ODM1NDNjOjc6ZDc2OTo4ZmRjNDk3NTkzZTJmNWNlZmQ3ZGI5ZjRhNDM1Y2M5NzEwYzEwZGM0ODc1NGI0NzAxMmE4M2ZhNWJmOWYzNTdjOnA6VDpG\" target=\"_blank\" rel=\"nofollow\">https:\/\/myriotx.com<\/a>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-37199","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/37199","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37199"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/37199\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37199"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37199"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37199"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}